Fresenius SE Comprehensive Income 2016-2024 | FSNUY
Fresenius SE comprehensive income from 2016 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Fresenius SE comprehensive income for the quarter ending September 30, 2024 was $-0.303B, a 164.85% decline year-over-year.
- Fresenius SE comprehensive income for 2023 was $0.019B, a 95.46% decline from 2022.
- Fresenius SE comprehensive income for 2022 was $0.429B, a 181.27% decline from 2021.
- Fresenius SE comprehensive income for 2021 was $-0.528B, a 59.3% decline from 2020.
Fresenius SE Annual Comprehensive Income
(Millions of US $) |
| 2023 |
$19 |
| 2022 |
$429 |
| 2021 |
$-528 |
| 2020 |
$-1,297 |
| 2019 |
$-213 |
| 2018 |
$-390 |
| 2017 |
$-450 |
| 2016 |
$580 |
| 2015 |
$311 |
Fresenius SE Quarterly Comprehensive Income
(Millions of US $) |
| 2024-09-30 |
$-303 |
| 2024-06-30 |
$274 |
| 2024-03-31 |
$182 |
| 2023-12-31 |
$19 |
| 2023-09-30 |
$468 |
| 2023-06-30 |
$120 |
| 2023-03-31 |
$157 |
| 2022-12-31 |
$429 |
| 2022-09-30 |
$1,675 |
| 2022-06-30 |
$809 |
| 2022-03-31 |
$-1 |
| 2021-12-31 |
$-528 |
| 2021-09-30 |
$-746 |
| 2021-06-30 |
$-972 |
| 2021-03-31 |
$-857 |
| 2020-12-31 |
$-1,297 |
| 2020-09-30 |
$-892 |
| 2020-06-30 |
$-282 |
| 2020-03-31 |
$-163 |
| 2019-12-31 |
$-213 |
| 2019-09-30 |
$170 |
| 2019-06-30 |
$-255 |
| 2019-03-31 |
$-179 |
| 2018-12-31 |
$-390 |
| 2018-09-30 |
$-464 |
| 2018-06-30 |
$-464 |
| 2018-03-31 |
$-766 |
| 2017-12-31 |
$-450 |
| 2017-09-30 |
$-375 |
| 2017-06-30 |
$-59 |
| 2017-03-31 |
$607 |
| 2016-12-31 |
$580 |
| 2016-09-30 |
$232 |
| 2016-06-30 |
$241 |
| 2016-03-31 |
$29 |
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$21.804B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
